Induced Pluripotent Stem Cell Market

Induced Pluripotent Stem Cell Market Outlook (2024 to 2034)

The global induced pluripotent stem cell market size is estimated to be US$ 2,013.3 million in 2024. The market is projected to register a CAGR of 7.1% and reach a valuation of US$ 3,980.8 million by 2034.

The market is predicted to rise owing to the increasing capital investments for the automation of iPSC production, rapid therapy product pipeline, and understanding of the functionality of omics-based data. Additionally, surging technological advancements are expected to propel market growth.

Tissue engineering and biotechnology firms are also investing in research and development to expand the scope of application of iPSCs and develop new stem cell therapies to treat various diseases, which is expected to drive market demand.

Key Drivers Propelling the Induced Pluripotent Stem Cell Market

• Increasing investments in research and development activities to advance the healthcare sector.
• Expanding the scope of application in induced pluripotent stem cells (iPSCs) in precision medicine.
• Surging government spending and rising knowledge about stem cell research in several organizations are pushing forth market growth.
• Rising incidences of chronic diseases and consequent spike in the usage of stem cells in medical treatments.
• Growing number of genomics projects, rising research funding, and surging deployment of genome engineering in personalized medicine are contributing to market expansion.

Report Attributes	Details
Estimated Market Value (2024E)	US$ 2,013.3 million
Forecasted Market Value (2034F)	US$ 3,980.8 million
Projected Growth Rate (2024 to 2034)	7.1%CAGR
Neurons Segment Growth Rate (2024 to 2034)	6% CAGR
Regenerative Medicine Segment Growth Rate (2024 to 2034)	6.6% CAGR
North America Market Share (2024)	48.7%
East Asia Market Share (2024)	17.2%
Key Companies Profiled in the Induced Pluripotent Stem Cell Industry Report	Sumitomo Dainippon Pharma Co. Ltd. Ncardia REPROCELL USA Inc. Thermo Fisher Scientific Inc. FUJIFILM Cellular Dynamics Inc. Fate Therapeutics Inc. Evotec SE Pluricell Biotech Cynata Therapeutics Limited Takara Bio Inc. ViaCyte Inc. Axol Bioscience Ltd. Others

Which Trend Augments the Induced Pluripotent Stem Cell Market Growth?

“Increasing Research-based Studies for iPSCs to Widen its Application Scope”

Surging iPSCs-based research studies are favoring the market’s progress. Presently, more than a hundred clinical trials are underway that deploy iPSCs for the development of iPSC products or disease intervention techniques. Moreover, the increasing knowledge about the benefits associated with induced pluripotent stem cells like the flexibility of ethical implications related to embryonic stem cells and removal of animal models are creating a conducive ground for business entities to deploy iPSCs in multiple applications. Some of the applications are toxicological tests, modeling diseases, new drugs, etc.

What are the Challenges Limiting the Induced Pluripotent Stem Cell Market?

“Restrictions in Therapeutic Applications of iPSC”

The primary obstacle that tampers with the therapeutic applications of iPSC includes the reprogramming method that uses retroviruses to complete. Retroviruses increase safety concerns, in addition to permanent integration of transgene and modification of copy number into the iPSC’s genome. Thus, reducing iPSC’s efficacy.

“Significant Expenses Related to Stem Cell Research and Therapies”

Expenditure related to stem cell research is significant. Stem cell research also takes a longer duration to develop and use induced pluripotent stem cells. These factors are restricting the uptake of iPSC. Additionally, ethical issues related to stem cell research and therapies are also constraining the market demand for iPSCs.

Region-wise Insights

Which Region Holds a Greater Share of the Induced Pluripotent Stem Cell Market?

“North America Boasts a Larger Share in the iPSC Market”

Attribute	Details
CAGR (2024 to 2034)	6%

The North America market is predicted to acquire a significant share of 48.7% in 2024. The regional market is estimated to obtain US$ 980 million in 2024 and is projected to expand at 6% over the forecast period. By 2034, the market size is expected to settle at US$ 1,762 million.

North America is observing an upsurge in multiple diseases, resulting in heightened demand for novel treatments. Due to this, many healthcare companies are creating unique treatments like regenerative and personalized medicine. Market players in the region are thus finding significant opportunities as stem cell research gains significant use in the development of regenerative and personalized medicine.

How is the East Asia Market Performing on the Global Platform?

“Growing Awareness about the Potential of Personalized Treatments in East Asia”

Attribute	Details
CAGR (2024 to 2034)	9.4%

The East Asia induced pluripotent stem cell market is anticipated to possess a value share of 17.2% in 2024. This region is estimated to attain US$ 347 million in 2024. By 2034, the regional market is projected to reach US$ 854 million, registering a CAGR of 9.4% through 2034. The market in East Asia is driven by rising economies, growing awareness about the potential of personalized treatments, and low-cost stem cell-based research.

Country-wise Insights

Which Country Leads the North America Market?

“The United States Acquires a Larger Share of the Regional Market”

Attribute	Details
CAGR (2024 to 2034)	5.7%

The United States induced pluripotent stem cell industry is expected to obtain a share of 91.8% in 2024. The market is estimated to accumulate US$ 899 million in 2024. By 2034, the market is expected to be valued at US$ 1,568 million, recording a CAGR of 5.7%.

The market growth is propelled by the increasing incidence of chronic diseases and enhanced healthcare infrastructure in the country. Additionally, private and government initiatives also have a strong impact on the market’s growth. Key players are employing strategic business models for the market’s growth.

Which Country is Emerging as a Lucrative Market in East Asia?

“Rapidly Rising Demand for Induced Pluripotent Stem Cells in Japan”

Attribute	Details
CAGR (2024 to 2034)	10%

The market in Japan is projected to record a CAGR of 10% through 2034. The market is estimated to extrapolate from US$ 134 million in 2024 to US$ 348 million by 2034. Based on value share, the market is estimated to occupy 38.6% share in 2024.

The market in Japan is anticipated to be driven by a high number of research universities and start-ups. The market is also catalyzed by collaborative efforts by international firms. New service or product launches in this country are also expected to propel market growth. Further, improving healthcare plans in Japan are also attracting investors and stakeholders.

Segment-wise Insights

Which Cell Type is Dominating the Market?

“Neurons Lead the Induced Pluripotent Stem Cell Market”

Attribute	Details
Market Share in 2024	30.9%

Neurons occupy a 30.9% market share in 2024. The segment is estimated to attain US$ 622.6 million in 2024. The segment is projected to register a 6% CAGR through 2034 and reach a value of US$ 1,115.6 million. The segment is driven by the rising research and development activities in the induced pluripotent stem cell market.

Which Application of iPSC Contributes to Market Growth?

“iPSC Finds Substantial Use in Regenerative Medicine”

Attribute	Details
Market Share in 2024	47.3%

Regenerative medicine obtains a 47.3% share in 2024. The segment is estimated to be valued at US$ 951.5 million in 2024, and rise at a CAGR of 6.6% through 2034. By 2034, the demand for iPSCs for regenerative medicine is expected to be worth US$ 1,799.4 million. The segment is driven by the expansion of applications and vigorous product pipelines by leading firms. In regenerative therapy, iPSCs can be seen proceeding with clinical trials. Thus, augmenting the segment’s growth.

Which End User Widely Employs iPSCs?

“Biotechnology Companies Capture a Massive Share of the Market”

Attribute	Details
Market Share in 2024	57.1%

Biotechnology companies occupy a 57.1% share in 2024. The segment is estimated to obtain US$ 1,149.0 million in 2024. Recording a CAGR of 6.6%, the segment is forecast to capture a value of US$ 2,179.4 million by 2034. The segment is driven by the presence and adoption of multiple kits, instruments, and consumables in addition to iPSC products.

Pharmaceutical and biotechnology companies are focusing on product launches via research and development efforts, creating market opportunities.

Competitive Landscape in the Induced Pluripotent Stem Cell Market

Key players in the induced pluripotent stem cell market include Sumitomo Dainippon Pharma Co. Ltd., Ncardia, REPROCELL USA Inc., Thermo Fisher Scientific Inc., FUJIFILM Cellular Dynamics Inc., Fate Therapeutics Inc., Evotec SE, Pluricell Biotech, Cynata Therapeutics Limited, Takara Bio Inc., ViaCyte Inc., Axol Bioscience Ltd., and Others.

Suppliers of induced pluripotent stem cells are raising their investments in research and development activities to enhance their portfolio for stem cell therapies, which is gaining traction for the treatment of many chronic diseases. Leading businesses are collaborating with other players to increase their customer base. Additionally, they are making strategic moves like partnership and acquisition to uplift their visibility and drive up the market competition.

Latest Developments in the Induced Pluripotent Stem Cell Market

• In August 2021, Fate Therapeutics officially announced that FT819 had been successful in treating its first patient in a clinical trial. FT819, which is a CAR-T cell treatment, was developed utilizing iPSCs.
• Bristol Myers Squibb and Century Therapeutics entered into a strategic partnership agreement in January 2022. Under this agreement, both companies are expected to work together to develop allogeneic cell treatments extracted from iPSCs to treat severe myeloid leukemia and many myelomas.
• In May 2022, Sernova and Evotec bonded over a strategic alliance to develop an iPSC-based beta replacement therapy for type 1 and 2 diabetes.
• In July 2021, SCM Lifescience Co. Ltd., which is a South Korea-based cell therapy developing firm, announced that it had in-license a diabetes drug from Allele Biotechnology and Pharmaceuticals, Inc. This drug is a pancreatic beta cell therapy extracted from iPSCs, and the deal has been signed at a valuation of US$ 0.75 million.

Segmentation of Induced Pluripotent Stem Cell Market Research

• By Cell Type:

  • Hepatocytes
  • Fibroblasts
  • Keratinocytes
  • Neurons
  • Others

• By Application Type:

  • Drug Development
  • Regenerative Medicine
  • Toxicity Testing

• By End User:

  • Academic and Research Institutes
  • Biotechnology Companies

• By Region:

  • North America
  • Europe
  • Latin America
  • East Asia
  • South Asia and Oceania
  • Middle East and Africa